Our friends at Oxfirst are hosting another interesting
webinar on March 14, 2018 at 15.00 BST and 16.00 CET.  The webinar is titled, “Are Important Innovations
Rewarded?  Evidence from Pharmaceutical
Markets.”  The presenter is Professor
Margaret Kyle.  
Here is a description of the presentation: 
This research focuses on the relationship between therapeutic
value and different measures of market rewards (the number of patents, price,
market share, and total revenues) of a new treatment. Using an assessment of
therapeutic value provided by the French Haute Authorité de Santé (HAS), I find
a weak relationship between most measures of rewards and this assessment of
therapeutic value, suggesting that the returns to developing a “me-too” product
are not very different from developing treatments with greater therapeutic
effects. One interpretation is that the HAS score is a poor assessment of
therapeutic value, in which case the use of similar health technology
assessments by governments and other payers should be re-examined.
Alternatively, if the HAS score is informative, the results suggest countries
are spending too much on less innovative products, and that a re-balancing of
innovation incentives may be worth considering if therapeutic value is highly
related to social welfare.
Here is Professor Kyle’s
biography: 
 
  | 
   
    | 
Prof. Margaret Kyle (MINES ParisTech and
    CEPR) currently holds the Chair in Intellectual Property and Markets for
    Technology at MINES ParisTech. Her research concerns innovation,
    productivity and competition. She has a number of papers examining R&D
    productivity in the pharmaceutical industry, specifically the role of
    geographic and academic spillovers; the firm-specific and policy
    determinants of the diffusion of new products; generic competition; and the
    use of markets for technology. Recent work examines the effect of trade and
    IP policies on the level, location and direction of R&D investment and
    competition. She also works on issues of innovation and access to therapies
    in developing countries. Her papers have been published in various journals
    of economics, strategy, and health policy, including the RAND Journal of
    Economics, Journal of Public Economics, Review of Economics
    and Statistics, Journal of Public Economics, Journal of Law
    and Economics, Antitrust Law Journal, Management Science, and Health
    Affairs.
 Margaret holds a PhD in economics from the Massachusetts Institute of
    Technology and is an associate editor of the International Journal of
    Industrial Organization. She previously held positions at Carnegie
    Mellon University, Duke University, London Business School, and the
    Toulouse School of Economics, and is a visiting professor at the Kellogg
    School of Management, Northwestern University. She has also been a visiting
    scholar at the Center for the Study of Innovation and Productivity at the
    Federal Reserve Bank of San Francisco and at the University of Hong Kong.
 |  |  | 
 
No comments:
Post a Comment